Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARQT | US
0.89
9.27%
Healthcare
Biotechnology
31/03/2024
05/07/2024
10.49
9.66
10.53
9.43
Arcutis Biotherapeutics Inc. a biopharmaceutical company focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151 a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154 a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252 a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255 a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234 a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis Inc. and changed its name to Arcutis Biotherapeutics Inc. in October 2019. Arcutis Biotherapeutics Inc. was incorporated in 2016 and is headquartered in Westlake Village California.
View LessPositive Momentum
Strength based on increasing price with high volume
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
66.5%1 month
88.4%3 months
80.8%6 months
98.4%-
-
13.20
0.92
0.43
-4.85
18.53
-
-194.94M
1.21B
1.21B
-
-63.79
-
1.68K
-119.24
7.89
27.88
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.32
Range1M
3.54
Range3M
6.18
Rel. volume
1.05
Price X volume
31.34M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Verona Pharma plc | VRNA | Biotechnology | 16.11 | 1.31B | 2.55% | n/a | 22.79% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 61.44 | 1.29B | 1.02% | 39.55 | 68.66% |
Arcus Biosciences Inc | RCUS | Biotechnology | 14.12 | 1.28B | -1.67% | n/a | 1.56% |
Ardelyx Inc | ARDX | Biotechnology | 5.29 | 1.24B | -0.56% | n/a | 69.54% |
immatics biotechnologies GmbH | IMTX | Biotechnology | 11.74 | 1.21B | -0.68% | n/a | 8.13% |
Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 13.71 | 1.20B | 1.56% | n/a | 0.10% |
NRIX | NRIX | Biotechnology | 19.47 | 1.19B | 0.31% | n/a | 17.28% |
IRON | IRON | Biotechnology | 46.62 | 1.15B | 4.93% | n/a | 0.60% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 5.09 | 1.13B | -2.49% | n/a | 28.28% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 21.15 | 1.09B | 1.44% | n/a | 2.36% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.85 | -2.43 | Cheaper |
Ent. to Revenue | 18.53 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 13.20 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 80.76 | 76.52 | Par |
Debt to Equity | 0.92 | 0.51 | Expensive |
Debt to Assets | 0.43 | 0.24 | Expensive |
Market Cap | 1.21B | 3.77B | Emerging |